Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma

Cancer Science

Volumn 102, Issue 3, 2011, Pages 648-655

  Sato, Ayuko ^a   Torii, Ikuko ^a   Tao, Li Hua ^a   Song, Misa ^a   Kondo, Nobuyuki ^b   Yoshikawa, Yoshie ^c   Hashimoto Tamaoki, Tomoko ^c   Hasegawa, Seiki ^b   Nakano, Takashi ^c   Tsujimura, Tohru ^a  

^a Departments of Pathology   (Japan)

^b General Thoracic Surgery   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETININ; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MONOCLONAL ANTIBODY D2-40;

ADULT; AGED; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INOCULATION; JAPANESE; LUNG METASTASIS; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM; METASTASIS; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; NUDE MOUSE; PERICARDIAL METASTASIS; PERITONEUM METASTASIS; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIB METASTASIS; THORACIC CAVITY; THORAX TUMOR; THORAX WALL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANIMALS; CELL LINE, TUMOR; FEMALE; GENES, NEUROFIBROMATOSIS 2; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PLEURAL NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 79951727570     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01827.x     Document Type: Article

References (28)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.
2. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081-90.
3. Philippeaux MM, Pache JC, Dahoun S et al. Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis. Histochem Cell Biol 2004; 122: 249-60.
4. Usami N, Fukui T, Kondo M et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006; 97: 387-94.
5. Kobayashi M, Takeuchi T, Ohtsuki Y. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status. Anticancer Res 2008; 28: 197-208.
6. Chahinian AP, Beranek JT, Suzuki Y et al. Transplantation of human malignant mesothelioma into nude mice. Cancer Res 1980; 40: 181-5.
7. Colt HG, Astoul P, Wang X, Yi ES, Boutin C, Hoffman RM. Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model. Anticancer Res 1996; 16: 633-9.
8. Le Pimpec-Barthes F, Bernard I, Abd Alsamad I et al. Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells. Br J Cancer 1999; 81: 1344-50.
9. Melotti A, Daga A, Marubbi D, Zunino A, Mutti L, Corte G. In vitro and in vivo characterization of highly purified human mesothelioma derived cells. BMC Cancer 2010; 10: 54.
10. Nakataki E, Yano S, Matsumori Y et al. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci 2006; 97: 183-91.
11. Martarelli D, Catalano A, Procopio A, Orecchia S, Libener R, Santoni G. Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer 2006; 6: 130.
12. Yanagihara K, Tsumuraya M, Takigahira M et al. An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy. Int J Cancer 2010; 126: 2835-46.
13. Addis B, Roche H. Problems in mesothelioma diagnosis. Histopathology 2009; 54: 55-68.
14. Husain AN, Colby TV, Ordonez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-31.
15. Sato A, Torii I, Okamura Y et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 2010; 23: 1458-66.
16. Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 1992; 9: 151-61.
17. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998; 110: 397-404.
18. Churg A, Colby TV, Cagle P et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000; 24: 1183-200.
19. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 2005; 129: 1421-7.
20. Stevens MW, Leong AS, Fazzalari NL, Dowling KD, Henderson DW. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol 1992; 8: 333-41.
21. Whitaker D. The cytology of malignant mesothelioma. Cytopathology 2000; 11: 139-51.
22. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int 2008; 58: 75-83.
23. Onofre FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Bocking A. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 2008; 114: 204-15.
24. Yokoyama T, Osada H, Murakami H et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 2008; 29: 2139-46.
25. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44: 46-53.
26. Feng Y, Xiao X, Zhu Z et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther 2009; 8: 1113-8.
27. Inamoto T, Yamada T, Ohnuma K et al. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 2007; 13: 4191-200.
28. Bidlingmaier S, He J, Wang Y et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 2009; 69: 1570-7.